What it is
GHK-Cu is a naturally occurring tripeptide — glycyl-histidyl-lysine — that binds copper with high affinity. It is present in human plasma and saliva, and its concentration declines with age. It is studied for its role in extracellular matrix remodeling, wound healing, and skin and hair biology.
In a clinical setting, GHK-Cu is available as an injectable compounded peptide and in topical formulations. The injectable form is not an FDA-approved pharmaceutical — it is compounded for off-label use under physician supervision. Topical copper peptide products are widely sold over the counter; their concentration, formulation, and delivery vary considerably and most do not approach the levels used in clinical studies.
How Dr. Brown approaches it
Peptide therapy at Esvie begins with a clinical consultation, not a phone order. Dr. Brown reviews your history, the indication you are seeking treatment for, and any contraindications before GHK-Cu is prescribed.
If GHK-Cu is appropriate, a written protocol is provided — route, dose, frequency, duration, and monitoring plan. Injectable peptide is sourced from a licensed compounding pharmacy. Topical use, when indicated, is integrated with the rest of your skincare protocol so products work together rather than against each other.
GHK-Cu is rarely a standalone treatment. It is most useful as an adjunct to a coordinated dermatologic plan — sun protection, retinoids when tolerated, in-office treatments where appropriate.
What to expect
Consultation: An in-person visit with Dr. Brown. Medical history, the specific indication, and how GHK-Cu fits with the rest of your plan.
Treatment cycle: For injectable protocols, subcutaneous administration on a schedule appropriate to the indication. Topical use is daily, integrated with your existing routine.
Monitoring: Check-in midway through the cycle and at completion. Adjustments are made based on response.
No downtime, no aftercare: Injection sites may be mildly tender briefly; nothing more.
Candidacy
Good candidates have a defined indication — skin quality, hair concerns, or tissue repair support — and understand that GHK-Cu is adjunctive, not a primary treatment.
Not a candidate if you are pregnant or nursing. Not a candidate with copper metabolism disorders such as Wilson’s disease. Not a candidate with active untreated malignancy. Not a candidate looking for GHK-Cu to replace evidence-based dermatologic care.
If GHK-Cu is not appropriate for your situation, Dr. Brown will say so and recommend the right starting point — which is often a well-built skincare routine and an in-office treatment plan before any peptide is added.